RxDoctor Payments Data

Amy Tseng, MD

Internal Medicine · Las Vegas, NVNPI 1497844104

Payments from drug & device makers

$4,171in general payments, 2019–2025

Across 125 payments — averaging $33.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$1K
  • AbbVie$517
  • Merz North America, Inc.$322
  • Johnson & Johnson$159
  • Lilly USA, LLC$147
  • plus $474 from 9 others

What the payments were for

  • Food & beverage$4,154100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,171 in reported general payments places this provider in the 85th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$112,575
Medicare patients
75
Services billed
1,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$65,545
FarxigaDapagliflozin Propanediol76$59,735
RybelsusSemaglutide33$38,563
JardianceEmpagliflozin23$19,561
Tresiba Flextouch U-200Insulin Degludec27$18,173
DapagliflozinDapagliflozin Propanediol21$17,105
VascepaIcosapent Ethyl28$15,769
TrulicityDulaglutide12$11,449
MounjaroTirzepatide11$10,039
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$2,444
Atorvastatin Calcium150$963
Metformin Hcl136$895
Telmisartan23$816
Albuterol Sulfate HfaAlbuterol Sulfate26$697
Fluticasone Propionate33$648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,130$104,10774 claims
AstraZenecaFarxiga$1,422$59,73576 claims
Lilly USA, LLCTrulicity, Mounjaro$147$21,48723 claims
Boehringer IngelheimJardiance$134$19,56123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →